GNF2133

Research use only, not for human use.

GNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes.

GNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes.(In Vitro):GNF2133 has an IC50 of >50 μM for GSK3β. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion.(In Vivo):In Diphtheria toxin A (RIP-DTA) mice, GNF2133 (3, 10, 30 mg/kg) significantly improves glucose disposal capacity and increased insulin secretion. In CD-1 mice, GNF2133 (30 mg/kg; p.o.) shows moderate plasma exposure and good oral absorption with oral bioavailability of 22.3%. In Wistar Han rat, GNF2133 (30 mg/kg; p.o.) increases in cell proliferation marker Ki67 and insulin and reduces cyclin D1 levels and overall cell density.

——

Others

Other Targets

VEGFR;Tyrosine Kinases

——

——

2561414-56-8

434.5

C24H30N6O2

>98% (HPLC)

——

O=C(NC1=NC=CC(=C1)C2=CN(C=3C=NC=CC23)C4CCOCC4)N5CCN(CC)CC5

——

(-20℃)

With Ice Pack

≥ 2 years